Link to this page
National Cancer Institute Thesaurus
| Preferred Name | Methylprednisolone Sodium Succinate | |
| Synonyms |
Asmacortone METHYLPREDNISOLONE SODIUM SUCCINATE Solu-Medrol A-MethaPred Solu Moderin Methylprednisolone Sodium Succinate Solu-Medrone Cryosolona Medrate Metypred Prednilem |
|
| Definitions |
The sodium succinate salt of a synthetic glucocorticoid receptor agonist with immunosuppressive and anti-inflammatory effects. Methylprednisolone sodium succinate is converted into active prednisolone in the body, which activates glucocorticoid receptor mediated gene expression. This includes inducing synthesis of anti-inflammatory protein IkappaB-alpha and inhibiting synthesis of nuclear factor kappaB (NF-kappaB). As a result, proinflammatory cytokine production such as IL-1, IL-2 and IL-6 is down-regulated and cytotoxic T-lymphocyte activation is inhibited. Therefore, an overall reduction in chronic inflammation and autoimmune reactions may be achieved. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C48004 |
|
| CAS_Registry |
2375-03-3
|
|
| Chemical_Formula |
C26H33O8.Na
|
|
| code |
C48004
|
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173381 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173383 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 |
|
| Contributing_Source |
CTRP FDA GDC
|
|
| DEFINITION |
The sodium succinate salt of a synthetic glucocorticoid receptor agonist with immunosuppressive and anti-inflammatory effects. Methylprednisolone sodium succinate is converted into active prednisolone in the body, which activates glucocorticoid receptor mediated gene expression. This includes inducing synthesis of anti-inflammatory protein IkappaB-alpha and inhibiting synthesis of nuclear factor kappaB (NF-kappaB). As a result, proinflammatory cytokine production such as IL-1, IL-2 and IL-6 is down-regulated and cytotoxic T-lymphocyte activation is inhibited. Therefore, an overall reduction in chronic inflammation and autoimmune reactions may be achieved.
|
|
| Display_Name |
Methylprednisolone Sodium Succinate
|
|
| FDA_UNII_Code |
LEC9GKY20K
|
|
| FULL_SYN |
Asmacortone METHYLPREDNISOLONE SODIUM SUCCINATE Solu-Medrol A-MethaPred Solu Moderin Methylprednisolone Sodium Succinate Solu-Medrone Cryosolona Medrate Metypred Prednilem
|
|
| Has_Free_Acid_Or_Base_Form | ||
| Has_Target | ||
| Is_Value_For_GDC_Property | ||
| label |
Methylprednisolone Sodium Succinate
|
|
| Legacy Concept Name |
Methylprednisolone_Sodium_Succinate
|
|
| Maps_To |
Methylprednisolone Sodium Succinate
|
|
| NSC Number |
48989
|
|
| Preferred_Name |
Methylprednisolone Sodium Succinate
|
|
| prefixIRI |
Thesaurus:C48004
|
|
| Semantic_Type |
Pharmacologic Substance
|
|
| UMLS_CUI |
C0700546
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |